title: Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells.
abstract: A human melanoma line genetically modified to release interleukin 4 (IL-4) was utilized to immunize advanced melanoma patients in order to elicit or increase a specific anti-melanoma immune response, which may affect distant lesions. Twelve metastatic melanoma patients were injected subcutaneously at least three times with 5 x 10(7) IL-4 gene-transduced and irradiated allogeneic melanoma cells per dose. Both systemic and local toxicities were mild, consisting of transient fever and erythema, swelling, and induration at the vaccination site. Two mixed but not complete or partial clinical responses were recorded. To assess the immune response of vaccinated patients, both serological and cell-mediated activities were evaluated. Antibodies to alloantigens could be detected in 2 of 11 patients tested. Mixed tumor-lymphocyte cultures were performed, utilizing autologous and allogeneic HLA-A2-matched melanoma lines as simulators and targets. A significant increase in IFN-gamma release was detected in 7 of 11 cases when postvaccination lymphocytes were stimulated by the untransduced allomelanoma cells. However, induction of a specific recognition of autologous melanoma cells by PBLs was obtained after vaccination in only one of six cases studied. This response involved the melanoma peptide Melan-A/MART-1(27-35) that was recognized in an HLA-A2-restricted fashion. These results indicate that vaccination with allogeneic melanoma cells releasing IL-4 locally can expand a T cell response against antigen(s) of autologous, untransduced tumor, although in a minority of patients.
authors.affiliation: Division of Experimental Oncology D, Instituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Arienti
authors.forename: F
authors.initials: F
authors.lastname: Belli
authors.forename: F
authors.initials: F
authors.lastname: Napolitano
authors.forename: J
authors.initials: J
authors.lastname: Sulé-Suso
authors.forename: A
authors.initials: A
authors.lastname: Mazzocchi
authors.forename: G F
authors.initials: GF
authors.lastname: Gallino
authors.forename: A
authors.initials: A
authors.lastname: Cattelan
authors.forename: C
authors.initials: C
authors.lastname: Santantonio
authors.forename: L
authors.initials: L
authors.lastname: Rivoltini
authors.forename: C
authors.initials: C
authors.lastname: Melani
authors.forename: M P
authors.initials: MP
authors.lastname: Colombo
authors.forename: N
authors.initials: N
authors.lastname: Cascinelli
authors.forename: M
authors.initials: M
authors.lastname: Maio
authors.forename: G
authors.initials: G
authors.lastname: Parmiani
authors.forename: C
authors.initials: C
authors.lastname: Sanantonio
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood; D019496:Cancer Vaccines / Q000008:administration & dosage*; D003602:Cytotoxicity, Immunologic; D005260:Female; D015316:Genetic Therapy; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000097:blood / Q000235:genetics*; D015850:Interleukin-6 / Q000097:blood; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D008545:Melanoma / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D014407:Tumor Cells, Cultured
chemical_list: D001323:Autoantibodies; D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D015850:Interleukin-6; D015847:Interleukin-4; D007371:Interferon-gamma